2025 Q4 -tulosraportti
14 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 750 | - | - | ||
| 287 | - | - | ||
| 1 300 | - | - | ||
| 800 | - | - | ||
| 30 000 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 716 041 | 716 041 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 716 041 | 716 041 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sitten · MuokattuNew analysis BioPorto announced yesterday the sale of its antibody business to Janel Life Sciences LLC for USD 10.5 million. The sale finances the company until H1 2028 without the need for further equity financing and thereby significantly reduces the financing risk. Cash flow break-even is now expected in H1 2028. 2026 revenue guidance is adjusted to DKK 38-48 million, while NGAL guidance remains unchanged at DKK 33-42 million. Read our analyst comment here: https://www.inderes.dk/analyst-comments/bioporto-saelger-antistofforretningen-for-usd-105-mio-finansiering-sikret-til-h1-2028
·17 t sittenWhen one constantly has to be ready to be swindled on the stock market, it's not easy to accept that the "platform" just lets things disappear. WHERE IS MY TEXT NOW? WHY DID IT DISAPPEAR? WILL YOU - NORDNET! - FEEL OBLIGED TO GIVE ME MY DOCUMENT AGAIN? OR IS IT YOU WHO JUST "WENT IN" HERE? These are quite relevant questions, when one thinks about it! WHERE DID MY TEXT GO ? ? ? ?- ·17 t sittenTHERE IS NOW A BASIS FOR A NEW TREND CHANNEL TO BE FORMED.·17 t sittenMy justification disappeared while I was working on the case!·17 t sittenI think I was at approx. 1.5 A4 pages, when Nordnet blinked, and it was gone! IS THAT REASONABLE NORDNET????!!!! I have now written to you and asked to get my "working text" back, so I ALSO have access TO: MY OWN WORDS! It is not unimportant! I WAS ABOUT TO DELIVER! How free should you be allowed to be present in the world?
- ·17 t sittenI have just now experienced the following: While I am in the process of making a LOOOONG write-up of REALLY HIGH QUALITY!, then POOF! it was suddenly! I think that is STRANGE NORDNET!!!! Will you go through your computers and give me my voice back? If I am on 1,5 A4-pages, then it seems REALLY WRONG that everything is suddenly deleted!
·20 t sittenAgain a really good Bioporto news here today at 15.15 : today at 15:16 ∙ GlobeNewswire April 2026 Announcement no. 7 BioPorto divests antibody business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 -- BioPorto A/S ("BioPorto" or "the Company") (CPH: BIOPOR) today announces the divestment of its antibody business to Janel Life Sciences LLC, a subsidiary of Janel Corporation. The transaction comprises BioPorto's antibody business and represents an important milestone in the implementation of the Company's strategy to strengthen its focus on promoting market adoption of the company's NGAL biomarker and open new opportunities for long-term growth. The total sales price amounts to 10.5 million USD, of which 9 million USD is paid at closing. An additional 1.5 million USD will be paid over the next three years as earn-out, provided that specific commercial milestones are reached. The agreement increases BioPorto's financial flexibility and provides financing that supports the Company's continued progress towards positive cash flow. With the divestment of the antibody business, the Company is expected to cover current anticipated expenses until the first half of 2028. With the divestment, the Company aspires to become cash-flow positive in the first half of 2028 without the need for further share issuance. This is provided that the strategic milestones previously communicated are successfully achieved. Carsten Buhl, CEO, commented: "We are very pleased to have completed this transaction. It marks an important strategic step in strengthening the focus on our core business area with the greatest growth potential. By divesting non-core activities, we free up capital and organizational capacity to accelerate growth as described in our "Forward" strategy plan. A plan focused on how BioPorto creates the most value in the long term. Therefore, we see this as an extremely positive development for the company and its shareholders."·3 t sittenThe NGAL test for adults will be FDA approved very quickly, because Bioporto's NGAL test for children is the benchmark at the FDA. I have pointed this out several times, and this information has at most received a raised eyebrow. If one is to attach any significance to the above, it naturally requires knowledge of what a benchmark means for Bioporto. It is very valuable for Bioporto that it is their own NGAL test for children against which the NGAL test for adults must be measured to obtain FDA approval. Because Bioporto's NGAL test for children is the benchmark, Bioporto has knowledge of how the NGAL test for adults should be developed. This again means that the FDA will expedite the process when the NGAL test for adults is to receive FDA approval, 510K. This again means that Bioporto will save both money and time. The above is the reason why I am very happy that the NGAL test for children has received benchmark status at the FDA.·2 t sittenBenchmark is fine. However, I think everyone who follows along even a little bit already knows that child ngal functions as a benchmark for the adult version. As the situation stands, the approval itself no longer seems to be the most interesting aspect, among other things because most probably expect adult ngal to be approved. The most interesting, i.e. most important, is the sales, meaning the expected sales. Regarding benchmark, I think it would be relevant to also look at the sales of child ngal as a benchmark for the expected sales of adult ngal. Unfortunately, we can ascertain that child ngal is still primarily sold for research, while it has not at all truly gained traction in daily hospital use. Why should hospitals start using ngal for adults when they clearly don't find value in using it for children??
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
14 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sitten · MuokattuNew analysis BioPorto announced yesterday the sale of its antibody business to Janel Life Sciences LLC for USD 10.5 million. The sale finances the company until H1 2028 without the need for further equity financing and thereby significantly reduces the financing risk. Cash flow break-even is now expected in H1 2028. 2026 revenue guidance is adjusted to DKK 38-48 million, while NGAL guidance remains unchanged at DKK 33-42 million. Read our analyst comment here: https://www.inderes.dk/analyst-comments/bioporto-saelger-antistofforretningen-for-usd-105-mio-finansiering-sikret-til-h1-2028
- ·17 t sittenWhen one constantly has to be ready to be swindled on the stock market, it's not easy to accept that the "platform" just lets things disappear. WHERE IS MY TEXT NOW? WHY DID IT DISAPPEAR? WILL YOU - NORDNET! - FEEL OBLIGED TO GIVE ME MY DOCUMENT AGAIN? OR IS IT YOU WHO JUST "WENT IN" HERE? These are quite relevant questions, when one thinks about it! WHERE DID MY TEXT GO ? ? ? ?
- ·17 t sittenTHERE IS NOW A BASIS FOR A NEW TREND CHANNEL TO BE FORMED.·17 t sittenMy justification disappeared while I was working on the case!·17 t sittenI think I was at approx. 1.5 A4 pages, when Nordnet blinked, and it was gone! IS THAT REASONABLE NORDNET????!!!! I have now written to you and asked to get my "working text" back, so I ALSO have access TO: MY OWN WORDS! It is not unimportant! I WAS ABOUT TO DELIVER! How free should you be allowed to be present in the world?
- ·17 t sittenI have just now experienced the following: While I am in the process of making a LOOOONG write-up of REALLY HIGH QUALITY!, then POOF! it was suddenly! I think that is STRANGE NORDNET!!!! Will you go through your computers and give me my voice back? If I am on 1,5 A4-pages, then it seems REALLY WRONG that everything is suddenly deleted!
- ·20 t sittenAgain a really good Bioporto news here today at 15.15 : today at 15:16 ∙ GlobeNewswire April 2026 Announcement no. 7 BioPorto divests antibody business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 -- BioPorto A/S ("BioPorto" or "the Company") (CPH: BIOPOR) today announces the divestment of its antibody business to Janel Life Sciences LLC, a subsidiary of Janel Corporation. The transaction comprises BioPorto's antibody business and represents an important milestone in the implementation of the Company's strategy to strengthen its focus on promoting market adoption of the company's NGAL biomarker and open new opportunities for long-term growth. The total sales price amounts to 10.5 million USD, of which 9 million USD is paid at closing. An additional 1.5 million USD will be paid over the next three years as earn-out, provided that specific commercial milestones are reached. The agreement increases BioPorto's financial flexibility and provides financing that supports the Company's continued progress towards positive cash flow. With the divestment of the antibody business, the Company is expected to cover current anticipated expenses until the first half of 2028. With the divestment, the Company aspires to become cash-flow positive in the first half of 2028 without the need for further share issuance. This is provided that the strategic milestones previously communicated are successfully achieved. Carsten Buhl, CEO, commented: "We are very pleased to have completed this transaction. It marks an important strategic step in strengthening the focus on our core business area with the greatest growth potential. By divesting non-core activities, we free up capital and organizational capacity to accelerate growth as described in our "Forward" strategy plan. A plan focused on how BioPorto creates the most value in the long term. Therefore, we see this as an extremely positive development for the company and its shareholders."·3 t sittenThe NGAL test for adults will be FDA approved very quickly, because Bioporto's NGAL test for children is the benchmark at the FDA. I have pointed this out several times, and this information has at most received a raised eyebrow. If one is to attach any significance to the above, it naturally requires knowledge of what a benchmark means for Bioporto. It is very valuable for Bioporto that it is their own NGAL test for children against which the NGAL test for adults must be measured to obtain FDA approval. Because Bioporto's NGAL test for children is the benchmark, Bioporto has knowledge of how the NGAL test for adults should be developed. This again means that the FDA will expedite the process when the NGAL test for adults is to receive FDA approval, 510K. This again means that Bioporto will save both money and time. The above is the reason why I am very happy that the NGAL test for children has received benchmark status at the FDA.·2 t sittenBenchmark is fine. However, I think everyone who follows along even a little bit already knows that child ngal functions as a benchmark for the adult version. As the situation stands, the approval itself no longer seems to be the most interesting aspect, among other things because most probably expect adult ngal to be approved. The most interesting, i.e. most important, is the sales, meaning the expected sales. Regarding benchmark, I think it would be relevant to also look at the sales of child ngal as a benchmark for the expected sales of adult ngal. Unfortunately, we can ascertain that child ngal is still primarily sold for research, while it has not at all truly gained traction in daily hospital use. Why should hospitals start using ngal for adults when they clearly don't find value in using it for children??
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 750 | - | - | ||
| 287 | - | - | ||
| 1 300 | - | - | ||
| 800 | - | - | ||
| 30 000 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 716 041 | 716 041 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 716 041 | 716 041 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
14 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sitten · MuokattuNew analysis BioPorto announced yesterday the sale of its antibody business to Janel Life Sciences LLC for USD 10.5 million. The sale finances the company until H1 2028 without the need for further equity financing and thereby significantly reduces the financing risk. Cash flow break-even is now expected in H1 2028. 2026 revenue guidance is adjusted to DKK 38-48 million, while NGAL guidance remains unchanged at DKK 33-42 million. Read our analyst comment here: https://www.inderes.dk/analyst-comments/bioporto-saelger-antistofforretningen-for-usd-105-mio-finansiering-sikret-til-h1-2028
- ·17 t sittenWhen one constantly has to be ready to be swindled on the stock market, it's not easy to accept that the "platform" just lets things disappear. WHERE IS MY TEXT NOW? WHY DID IT DISAPPEAR? WILL YOU - NORDNET! - FEEL OBLIGED TO GIVE ME MY DOCUMENT AGAIN? OR IS IT YOU WHO JUST "WENT IN" HERE? These are quite relevant questions, when one thinks about it! WHERE DID MY TEXT GO ? ? ? ?
- ·17 t sittenTHERE IS NOW A BASIS FOR A NEW TREND CHANNEL TO BE FORMED.·17 t sittenMy justification disappeared while I was working on the case!·17 t sittenI think I was at approx. 1.5 A4 pages, when Nordnet blinked, and it was gone! IS THAT REASONABLE NORDNET????!!!! I have now written to you and asked to get my "working text" back, so I ALSO have access TO: MY OWN WORDS! It is not unimportant! I WAS ABOUT TO DELIVER! How free should you be allowed to be present in the world?
- ·17 t sittenI have just now experienced the following: While I am in the process of making a LOOOONG write-up of REALLY HIGH QUALITY!, then POOF! it was suddenly! I think that is STRANGE NORDNET!!!! Will you go through your computers and give me my voice back? If I am on 1,5 A4-pages, then it seems REALLY WRONG that everything is suddenly deleted!
- ·20 t sittenAgain a really good Bioporto news here today at 15.15 : today at 15:16 ∙ GlobeNewswire April 2026 Announcement no. 7 BioPorto divests antibody business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 -- BioPorto A/S ("BioPorto" or "the Company") (CPH: BIOPOR) today announces the divestment of its antibody business to Janel Life Sciences LLC, a subsidiary of Janel Corporation. The transaction comprises BioPorto's antibody business and represents an important milestone in the implementation of the Company's strategy to strengthen its focus on promoting market adoption of the company's NGAL biomarker and open new opportunities for long-term growth. The total sales price amounts to 10.5 million USD, of which 9 million USD is paid at closing. An additional 1.5 million USD will be paid over the next three years as earn-out, provided that specific commercial milestones are reached. The agreement increases BioPorto's financial flexibility and provides financing that supports the Company's continued progress towards positive cash flow. With the divestment of the antibody business, the Company is expected to cover current anticipated expenses until the first half of 2028. With the divestment, the Company aspires to become cash-flow positive in the first half of 2028 without the need for further share issuance. This is provided that the strategic milestones previously communicated are successfully achieved. Carsten Buhl, CEO, commented: "We are very pleased to have completed this transaction. It marks an important strategic step in strengthening the focus on our core business area with the greatest growth potential. By divesting non-core activities, we free up capital and organizational capacity to accelerate growth as described in our "Forward" strategy plan. A plan focused on how BioPorto creates the most value in the long term. Therefore, we see this as an extremely positive development for the company and its shareholders."·3 t sittenThe NGAL test for adults will be FDA approved very quickly, because Bioporto's NGAL test for children is the benchmark at the FDA. I have pointed this out several times, and this information has at most received a raised eyebrow. If one is to attach any significance to the above, it naturally requires knowledge of what a benchmark means for Bioporto. It is very valuable for Bioporto that it is their own NGAL test for children against which the NGAL test for adults must be measured to obtain FDA approval. Because Bioporto's NGAL test for children is the benchmark, Bioporto has knowledge of how the NGAL test for adults should be developed. This again means that the FDA will expedite the process when the NGAL test for adults is to receive FDA approval, 510K. This again means that Bioporto will save both money and time. The above is the reason why I am very happy that the NGAL test for children has received benchmark status at the FDA.·2 t sittenBenchmark is fine. However, I think everyone who follows along even a little bit already knows that child ngal functions as a benchmark for the adult version. As the situation stands, the approval itself no longer seems to be the most interesting aspect, among other things because most probably expect adult ngal to be approved. The most interesting, i.e. most important, is the sales, meaning the expected sales. Regarding benchmark, I think it would be relevant to also look at the sales of child ngal as a benchmark for the expected sales of adult ngal. Unfortunately, we can ascertain that child ngal is still primarily sold for research, while it has not at all truly gained traction in daily hospital use. Why should hospitals start using ngal for adults when they clearly don't find value in using it for children??
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 750 | - | - | ||
| 287 | - | - | ||
| 1 300 | - | - | ||
| 800 | - | - | ||
| 30 000 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 716 041 | 716 041 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 716 041 | 716 041 | 0 | 0 |